Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yuanyang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1898-7897; OpenAlex author ID A5019831715. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2021: 3 papers · 2022: 5 papers · 2023: 6 papers · 2024: 3 papers · 2025: 2 papers

Papers 19

  1. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  2. RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis. Co-author DOI 10.1126/sciadv.adw9519↗
  3. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-024-00925-x↗
  4. FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3638↗
  5. Construction of a prognostic model with exosome biogenesis- and release-related genes and identification of RAB27B in immune infiltration of pancreatic cancer. Co-author DOI 10.21037/tcr-24-54↗
  6. Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-023-00897-4↗
  7. Prognostic value and immune infiltration of ARMC10 in pancreatic adenocarcinoma via integrated bioinformatics analyses. Co-author DOI 10.1016/j.heliyon.2023.e20464↗
  8. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. First author DOI 10.1038/s41419-023-05711-5↗
  9. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Co-author DOI 10.1186/s12967-023-04043-4↗
  10. Pancreatic cancer stemness: dynamic status in malignant progression. Co-author DOI 10.1186/s13046-023-02693-2↗
  11. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pgen.1010847↗
  12. Phospholipase A/acyltransferase 4 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. First author DOI 10.1016/j.heliyon.2022.e10416↗
  13. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. Co-author DOI 10.1186/s12935-022-02768-8↗
  14. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs. Co-author DOI 10.1186/s12935-022-02785-7↗
  15. Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugs Co-author DOI 10.21203/rs.3.rs-1759071/v2↗
  16. Long Noncoding RNA and Circular RNA: Two Rising Stars in Regulating Epithelial-Mesenchymal Transition of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.910678↗
  17. Mobius strip in pancreatic cancer: biogenesis, function and clinical significance of circular RNAs. Co-author DOI 10.1007/s00018-021-03908-5↗
  18. IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/β-catenin signaling. Co-author DOI 10.1007/s13402-021-00651-8↗
  19. The role of autophagy in pancreatic cancer progression. Co-author DOI 10.1016/j.bbcan.2021.188592↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bangbo Zhao · 16 shared papers, 2021–2024 · strength 2.87
  2. Zeru Li · 15 shared papers, 2021–2024 · strength 2.70
  3. Weibin Wang · 14 shared papers, 2021–2024 · strength 2.48
  4. Xiaoying Yang · 12 shared papers, 2021–2024 · strength 2.06
  5. Cheng‐Feng Qin · 11 shared papers, 2021–2024 · strength 2.00
  6. Tianyu Li · 7 shared papers, 2022–2023 · strength 1.26
  7. Yutong Zhao · 5 shared papers, 2022–2023 · strength 0.94
  8. Tianhao Li · 5 shared papers, 2021–2024 · strength 0.84
  9. Tianhao Li · 5 shared papers, 2022–2023 · strength 0.83
  10. Xingtong Zhou · 4 shared papers, 2021–2024 · strength 0.71
  11. Taiping Zhang · 3 shared papers, 2024–2025 · strength 0.60
  12. Gang Yang · 3 shared papers, 2021–2025 · strength 0.57
  13. Cheng Qin · 3 shared papers, 2022–2023 · strength 0.53
  14. Jinxin Tao · 2 shared papers, 2024–2025 · strength 0.39
  15. Yueze Liu · 2 shared papers, 2024–2025 · strength 0.39
  16. Wenhao Luo · 2 shared papers, 2024–2025 · strength 0.39
  17. Jiangdong Qiu · 2 shared papers, 2024–2025 · strength 0.39
  18. Weibin Wang · 2 shared papers, 2023 · strength 0.39
  19. Cheng Yong Qin · 2 shared papers, 2022–2023 · strength 0.34
  20. Tianyu Li · 1 shared paper, 2024 · strength 0.24
  21. Yuying Liu · 1 shared paper, 2025 · strength 0.21
  22. Zhe Cao · 1 shared paper, 2025 · strength 0.20
  23. Tao Liu · 1 shared paper, 2025 · strength 0.20
  24. Jianchun Xiao · 1 shared paper, 2025 · strength 0.20
  25. Hao Chen · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.